Identification of candidate variants in plasma associated with early versus late disease progression under anti-PD-1 therapy in metastatic NSCLC.
- DOI
- 10.21037/tlcr-2026-0463
- Published
- 2026 Aug 31
- Container
- Translational lung cancer research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.21037/tlcr-2026-0463,
title = {Identification of candidate variants in plasma associated with early versus late disease progression under anti-PD-1 therapy in metastatic NSCLC.},
author = {Rodriguez-Casanova A and Mondelo-Macía P and Leon-Mateos L and García-González J and Costa-Fraga N and Dubbelman J and Gómez-García MÁ and Lorenzo-Gómez I and Abalo A and Muinelo-Romay L and López-López R and Díaz-Lagares A},
year = {2026},
journal = {Translational lung cancer research},
doi = {10.21037/tlcr-2026-0463},
url = {https://doi.org/10.21037/tlcr-2026-0463}
}RIS
TY - JOUR TI - Identification of candidate variants in plasma associated with early versus late disease progression under anti-PD-1 therapy in metastatic NSCLC. AU - Rodriguez-Casanova A AU - Mondelo-Macía P AU - Leon-Mateos L AU - García-González J AU - Costa-Fraga N AU - Dubbelman J AU - Gómez-García MÁ AU - Lorenzo-Gómez I AU - Abalo A AU - Muinelo-Romay L AU - López-López R AU - Díaz-Lagares A PY - 2026 JO - Translational lung cancer research DO - 10.21037/tlcr-2026-0463 UR - https://doi.org/10.21037/tlcr-2026-0463 ER -
APA
A, R., P, M., L, L., J, G., N, C., J, D., MÁ, G., I, L., A, A., L, M., R, L., & A, D. (2026). Identification of candidate variants in plasma associated with early versus late disease progression under anti-PD-1 therapy in metastatic NSCLC.. Translational lung cancer research. https://doi.org/10.21037/tlcr-2026-0463
Source records
- pubmed · retrieved 2026-09-25T15:02:01.483Z